Quest Diagnostics Declares Quarterly Cash Dividend
Werte in diesem Artikel
SECAUCUS, N.J., Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics common stock on October 4, 2024.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from the world's largest database of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-302222903.html
SOURCE Quest Diagnostics
Ausgewählte Hebelprodukte auf Quest Diagnostics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Quest Diagnostics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Quest Diagnostics Inc.
Analysen zu Quest Diagnostics Inc.
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2018 | Quest Diagnostics Overweight | Barclays Capital | |
20.10.2017 | Quest Diagnostics Buy | Mizuho | |
25.07.2017 | Quest Diagnostics Buy | Mizuho | |
05.06.2017 | Quest Diagnostics Buy | Mizuho | |
12.05.2017 | Quest Diagnostics Hold | Argus Research Company |
Datum | Rating | Analyst | |
---|---|---|---|
25.06.2018 | Quest Diagnostics Overweight | Barclays Capital | |
20.10.2017 | Quest Diagnostics Buy | Mizuho | |
25.07.2017 | Quest Diagnostics Buy | Mizuho | |
05.06.2017 | Quest Diagnostics Buy | Mizuho | |
26.04.2017 | Quest Diagnostics Buy | Mizuho |
Datum | Rating | Analyst | |
---|---|---|---|
12.05.2017 | Quest Diagnostics Hold | Argus Research Company | |
07.03.2017 | Quest Diagnostics Equal Weight | Barclays Capital | |
21.10.2016 | Quest Diagnostics Neutral | Mizuho | |
22.04.2016 | Quest Diagnostics Equal Weight | Barclays Capital | |
22.04.2016 | Quest Diagnostics Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quest Diagnostics Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen